CRASH-3

From Wiki Journal Club
Jump to: navigation, search
Roberts I, et al. "Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial". The Lancet. 2019. :.
PubMedFull textPDFClinicalTrials.gov

Clinical Question

Bottom Line

Major Points

Guidelines

As of June 2018, no guidelines have been published that reflect the results of this trial.

Design

  • Multicenter, double-blind, parallel-group, randomized, controlled trial
  • N=12737
    • Intervention (n=)
    • Placebo (n=)
  • Setting:
  • Enrollment: July 20, 2012 and January 31, 2019
  • Mean follow-up:
  • Analysis:
  • Primary Outcome:

Population

Inclusion Criteria

Exclusion Criteria

Baseline Characteristics

BLANK Group displayed

  • Demographics:
  • Physiologic parameters:
  • Anthropomorphics: Weight
  • Labs:
  • Site of infection

Interventions

Outcomes

Comparisons are BLANK therapy vs. BLANK therapy.

Primary Outcomes

Secondary Outcomes

Subgroup Analysis

Adverse Events

Criticisms

Funding

  • Run in phase (first 500 patients): The JP Moulton Charitable Trust
  • Main phase: the National Institute for Health Research Health Technology Assessment (NIHR HTA; 14/190/01), and Joint Global Health Trials, Medical Research Council, Department for International Development, Global Challenges Research Fund, and the Wellcome Trust (MRM0092111)
  • New Brunswick Trauma Program grant of $10 000 CAD to support the trial in Canada

Further Reading